Overview
Current Appointments & Affiliations
Professor of Medicine
·
2018 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
1993 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study.
Journal Article Lancet Haematol · June 27, 2025 BACKGROUND: The phase 3 BELLINI primary endpoint was met, showing superior progression-free survival with venetoclax versus placebo plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma as assessed by an independent rev ... Full text Link to item CiteFood insecurity prior to hematopoietic stem cell transplant is associated with malnutrition and worse outcomes.
Journal Article Bone Marrow Transplant · June 2025 Food insecurity (FI), defined as the lack of continuous access to adequate food, affects 17-55% of cancer patients. Effects may be exacerbated in hematopoietic stem cell transplant (HSCT) patients, who face nutritional challenges due to treatment side effe ... Full text Link to item CiteTreatment Patterns, Efficacy, and Tolerability of Belantamab Mafodotin in Patients With Relapsed and/or Refractory Multiple Myeloma: A Real-World Analysis.
Journal Article Clin Lymphoma Myeloma Leuk · April 15, 2025 PURPOSE: Belantamab mafodotin is an anti-B cell maturation antigen (BCMA) immunoconjugate for patients with relapsed/refractory multiple myeloma (RRMM). Additional data on its treatment patterns, efficacy, and tolerability in real-world settings are needed ... Full text Link to item CiteRecent Grants
Celgene: CA057-001 - A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480, BORTEZOMIB AND DEXAMETHASONE (480Vd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYE
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2024 - 2029A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2024 - 2029A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Clinical TrialPrincipal Investigator · Awarded by Caribou Biosciences, Inc. · 2023 - 2028View All Grants
Education, Training & Certifications
Sapienza University of Rome (Italy) ·
1986
M.D.